Ambrx To Present Phase I/II Clinical Data For Optimized, Long Acting ... - Medical News Today
Ambrx Inc. announced the scheduled presentation of data from a Phase I/II clinical trial of ARX201, the company's long-acting human growth hormone (hGH) analogue developed in collaboratio...
